[Cardiac amyloidosis. Comment on the case report by Brychta et al: Restrictive cardiomyopathy as a manifestation of primary amyloidosis].

P Gregor

Vnitr Lek 2004, 50(1):6

[Are we prepared for the expected increase in cardioverter-defibrillator implantation?].

J Bytesník

Vnitr Lek 2004, 50(1):7-10

[Chronic myeloid leukemia and imatinib mesylate therapy].

L Chrobák

Vnitr Lek 2004, 50(1):10-12

[Prognosis as a logical medical consideration].

J Zaloudík

Vnitr Lek 2004, 50(1):12-13

[Chronic venous insufficiency--outpatient study of risk factors].

D Musil, J Herman

Vnitr Lek 2004, 50(1):14-20

The aim of the clinical study was to monitor and analyse possible causes of chronic venous insufficiency (CVI) in a randomised sample of patients with diagnosed CVI. There were 100 patients in the investigated sample, 82 women of an average age of 40.4 years and 18 men of an average age of 42.7 years. Monitoring of risk factors of development and advancement of CVI in our sample of patients showed following results: 1. frequent overweight and obesity (BMI > 25 kg/m2) in women (47.6%) and men (83%) with relatively frequent cases when a patient put on weight more than 5 kg within the last 5 years before development of CVI signs (24.4% of women and...

[Imatinib mesylate (Glivec) in treatment of chronic phase chronic myeloid leukemia].

J Voglová, A Poznarová, L Chrobák, J Rabasová, M Beránek, J Moravcová, E Faber, H Klamová, M Cikhart

Vnitr Lek 2004, 50(1):21-3,

The new knowledge in molecular biology and pathophysiology of chronic myeloid leukemia enabled the development of imatinib mesylate (Glivec, formerly STI571). Imatinib potently inhibits several protein tyrosine kinases, including BCR-ABL, c-Kit, and PDGF receptor. Imatinib blocks the phosphorylation of downstream target proteins and interrupts the malignant transformation leading to the development of CML. Phase I and II studies demonstrated that imatinib is highly effective and well tolerated in all phase of CML. We got our experience with imatinib on more than two-year monitoring 34 patients within the Expanded Access Study CST1571 0113. Imatinib...

[Successful treatment of chronic hepatitis C in hemophiliacs based on historical development of therapeutic protocols].

P Husa, P Smejkal, L Husová, P Chalupa, M Penka

Vnitr Lek 2004, 50(1):30-35

Chronic infection with hepatitis C virus is very frequent among hemophilic patients in all developed counties, including the Czech Republic. Because of a possibility of developing serious terminal stages of infection, liver cirrhosis and hepatocellular carcinoma, the tendency in treatment of patients with chronic hepatitis C is to start it as soon as possible and thus reduce the probability of developing these advanced stages of disease which are difficult to treat. Treatment of hemophilic patients with chronic hepatitis C started in the Department of Infectious Diseases, University Hospital Brno Bohunice, in 1996. Used treatment schemes have reflected...

[Thrombin activatable fibrinolysis inhibitor (TAFI) and its importance in the regulation of fibrinolysis].

J Stasko, J Hudecek, P Kubisz

Vnitr Lek 2004, 50(1):36-44

Thrombin activatable fibrinolysis inhibitor (TAFI) also named procarboxypeptidase U (CPU), procarboxypeptidase R (CPR) and plasma procarboxypeptidase B (CPB) provides an important link between fibrinolysis and coagulation cascade. Activated TAFI (TAFIa) reduces a generation of plasmin because it cleaves off the carboxy-terminal lysine residues from partially degraded fibrin and thereby abrogates the fibrin cofactor function in the tPA-mediated catalysis of plasminogen to plasmin. TAFI is activated by thrombin-thrombomodulin complex. TAFI transformation to the activated TAFI (TAFIa) induced by thrombin supports the important role of coagulation cascade...

[Importance of immunophenotyping in the diagnosis of B-cell lymphoproliferative diseases ].

D Prausová, J Krejsek, P Zák, J Voglová, D Belada

Vnitr Lek 2004, 50(1):45-53

The immunophenotyping of the lymphoproliferative diseases is considered to be an integral part of the diagnostic process pointing to the correct classification of the individual diseases and to the choice of the most suitable type of therapy. This article describes the immunophenotype of particular types of B-lymphoproliferative disorders included in the World Health Organization classification (WHO) and the prognostic importance of some markers. The panel of specific monoclonal antibodies directed to B-cell lineage used in our department is displayed.

[Care of patients with implanted cardioverters-defibrillators: what every physician should know].

L Krivan, M Sepsi, B Semrád

Vnitr Lek 2004, 50(1):54-60

Implantable cardioverter defibrillators have become an integral part of treatment of patients with malignant chamber arrhythmias over last 10 years both in secondary and primary prevention of sudden deaths. Based on monitoring of a group of 182 patients and based on information in literature, authors present a survey of the most frequent situations, rules and complications related to therapy with implantable defibrillators. In the end they try to answer summary of the most frequent questions of internal medicine physicians and GPs concerning patients with this implanted device.

[Prognosis and prognostic factors in oncology and oncologic surgery ].

E A Gorbunov, J Wechsler

Vnitr Lek 2004, 50(1):61-65

At present time, we can see increasing interest in prognosis and prognostic factors. This review refers to the problems of prognostics in oncology and oncosurgery. Authors emphasize importance of prognosis and its integrating role in issues of treatment tactics and strategy selection. This article presents main classification of prognostic factors, e.g. the subject-based one, which consists of three groups-tumor-related, host-related and environment related factors. Factors that belong to the first group are anatomic extent of disease that is classified according to the TNM classification, tumor histopathologic factors and a great number of molecular...

[Restrictive cardiomyopathy as a manifestation of primary amyloidosis].

T Brychta, J Parenica, T Zatocil, J Manousek, M Tesák, J Schildberger, P Kala, B Semrád, J Brázdil, M Cíhalová

Vnitr Lek 2004, 50(1):66-71

Primary amyloidosis is a rare disease, cardiac involvement occurs in up to 40% of patients. Diffuse amyloid deposits cause an impairment of myocardial systolic and diastolic function. In this paper we are presenting a case of a 54-year-old woman. The woman was admitted because of progressive fatigue, dyspnoea, chest pain, later she experienced hypotension, dyspepsia, and enterorrhagia. ECG showed decrease in QRS amplitude. We have found an echocardiographic evidence of wall hypertrophy. Right cardiac catheterization showed a restrictive situation. Immunobinding of serum and urine revealed monoclonal kappa light chains. The diagnosis was determined...

[Disagreement between findings of 99mTc-MIBI and 99mTc-pertechnetate scintigraphy scans in patients with primary hyperparathyroidism].

J Dolezal, J Horácek, V Ceeová, J Vizďa

Vnitr Lek 2004, 50(1):72-75

Sixty-two-year-old man was admitted to hospital for increased serum level of calcium (3.85 mmol/l) and incipient renal failure (urea 7.2 mmol/l, kreatinin 117 mumol/l). The reason of hypercalcaemia was intensive explored. Serum level of intact PTH was 383.6 pg/ml. We performed two-dimensional early and delayed (2 hours) scintigram after intravenous administration of 750 MBq 99mTc-sestamibi, i.e. double-phase technique. There was detected focus (diameter 20 mm) of increased sestamibi uptake with slow wash-out in distal part right thyroid lobe. Planar scintigraphy obtained after intravenous administration of 185 MBq 99mTc-pertechnetate detected focus...

[An effective vaccine against Ebola hemorrhagic fever].

Leopold Pospísil

Vnitr Lek 2004, 50(1):76